Tom Powles, Head of Solid Tumor Research at Barts Cancer Institute, shared a post on X about a paper by
“The +ve perioperative EVP trial for OS in cis ineligible MIBC may open a new area.
Especially if it’s like EVP in M1 disease. 3 more trials in this area are awaited, which test
- EVP vs cisplatin (NIAGARA population),
- EV/PD1/CTLA4 vs surgery
- treatment based on ctDNA status.”
More posts featuring Tom Powles.